CTS-2090
/ Histogen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 16, 2023
Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
(GlobeNewswire)
- "We believe this key patent provides broad coverage for Histogen’s portfolio of highly selective and orally active anti-inflammatory caspase inhibitors, including CTS-2090. This patent includes information that CTS-2090 has demonstrated potent oral activity in a well characterized model of ulcerative colitis. Importantly, CTS-2090 provided statistically significant protection against inflammation-driven damage to the lining of the GI tract and also protected against loss of body weight."
Patent • Immunology
April 15, 2019
Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
(GlobeNewswire, Conatus Pharmaceuticals Inc.)
- The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) detailed results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor. In collaboration with Novartis, Conatus is developing its lead in-licensed compound, emricasan, for the treatment of patients with NASH-driven chronic liver diseases.
Clinical • Clinical data • Late-breaking abstract • P2b data
1 to 2
Of
2
Go to page
1